METHODS	After a single-blind placebo run-in period , adults ( n = 488 ) experiencing manic or mixed episodes were randomized to flexible-dose sublingual asenapine ( 10 mg BID on day 1 ; 5 or 10 mg BID thereafter ; n = 194 ) , placebo ( n = 104 ) , or oral olanzapine ( 15 mg BID on day 1 ; 5-20 mg QD thereafter ; n = 191 ) .\